CN

Charu Naithani

Active Director Director DIN 07483065
DIN 07483065 First appointment Aug 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2017
Shareholding value •••• Premium profile

About Charu Naithani

Data last updated:

Charu Naithani is a Director at Cysum Pharmaceuticals Private Limited (since 2017). The company operates in Pharma. Cysum Pharmaceuticals Private Limited reported revenue of ₹4.2 Lakh (FY 2025).

DIN 07483065
Primary Designation Director
Industry Pharma
First Appointment 22 Aug 2017
Oldest Company Age 9 yrs
Largest company Cysum Pharmaceuticals Private Limited · ₹4.2 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 Aug 20172017₹4.2 Lakh (FY 2025)Active

Board colleagues of Charu Naithani

Directorship timeline

Open interactive timeline →
Cysum Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Charu Naithani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Charu Naithani

Charu Naithani currently holds 1 directorship: Cysum Pharmaceuticals Private Limited (Director, since 22 Aug 2017, revenue ₹4.2 Lakh (FY 2025)).

Charu Naithani was first appointed on 22 Aug 2017 as Director at Cysum Pharmaceuticals Private Limited.

The current boards of Charu Naithani's companies include Madhwa Nand Khanduri (Cysum Pharmaceuticals Private Limited), Trilok Chandra Naithani (Cysum Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available